Literature DB >> 8054449

Increased activated protein C-protein C inhibitor complex level in patients positive for lupus anticoagulant.

T Nakase1, H Wada, K Minamikawa, Y Wakita, M Shimura, K Hiyoyama, S Tamaki, S Shirakawa, K Deguchi, J Nisioka.   

Abstract

Activated protein C (APC)-protein C inhibitor (PCI) complex and APC-alpha 1antitrypsin (alpha 1AT) complex levels were measured in 29 patients positive for lupus anticoagulant (LA). LA was considered positive if two of the following three criteria were fulfilled: (1) prolongation of the activated partial thromboplastin time, (2) prolongation of the kaolin clotting time (KCT) and KCT mixing test, and (3) prolongation of the dilute Russell's viper venom time (DRVVT) and DRVVT/DRVVT with high lipid concentration. Plasma thrombin-antithrombin III (AT-III) complex and plasmin-alpha 2-antiplasmin inhibitor complex levels in patients positive for LA were increased slightly, but not significantly, and FDP-D-dimer and t-PA levels were not markedly increased. Plasma PAI-1 level in the LA-positive patients was significantly increased compared with normal volunteers. AT-III activity, protein C antigen, PCI antigen, and protein S antigen levels in the LA-positive patients were virtually normal, while protein C activity was slightly, but not significantly, decreased. APC-PCI complex level was increased in all LA-positive patients, and was not detectable in patients with systemic lupus erythematosus and normal volunteers. APC-alpha 1AT complex was increased slightly, in only two LA-positive patients; it was not detectable in the other patients or in the normal volunteers. These findings suggest that patients positive for LA are in a hypercoagulable state and that protein C activity in such patients is decreased, due to the activation of this protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8054449     DOI: 10.1097/00001721-199404000-00003

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  2 in total

1.  Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.

Authors:  Y H Lee; G G Song
Journal:  Z Rheumatol       Date:  2021-05       Impact factor: 1.372

2.  Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials.

Authors:  Y H Lee; G G Song
Journal:  Z Rheumatol       Date:  2020-12-18       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.